Short Interest in Centessa Pharmaceuticals plc (NASDAQ:CNTA) Rises By 31.6%

Centessa Pharmaceuticals plc (NASDAQ:CNTA) was the target of a large increase in short interest during the month of February. As of February 28th, there was short interest totalling 5,460,000 shares, an increase of 31.6% from the February 13th total of 4,150,000 shares. Currently, 6.9% of the shares of the company are short sold. Based on an average daily volume of 772,500 shares, the short-interest ratio is presently 7.1 days.

Insider Buying and Selling

In other Centessa Pharmaceuticals news, CTO Tia L. Bush sold 11,000 shares of the stock in a transaction on Monday, February 3rd. The stock was sold at an average price of $16.86, for a total transaction of $185,460.00. Following the transaction, the chief technology officer now owns 121,503 shares in the company, valued at $2,048,540.58. This trade represents a 8.30 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Saurabh Saha sold 55,000 shares of the business’s stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $17.44, for a total transaction of $959,200.00. Following the completion of the sale, the chief executive officer now directly owns 520,661 shares of the company’s stock, valued at approximately $9,080,327.84. The trade was a 9.55 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 247,168 shares of company stock valued at $4,138,928. Insiders own 11.59% of the company’s stock.

Hedge Funds Weigh In On Centessa Pharmaceuticals

A number of institutional investors have recently modified their holdings of the business. Price T Rowe Associates Inc. MD boosted its stake in Centessa Pharmaceuticals by 14.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 5,364,392 shares of the company’s stock valued at $89,854,000 after buying an additional 685,371 shares in the last quarter. Adage Capital Partners GP L.L.C. lifted its holdings in shares of Centessa Pharmaceuticals by 22.0% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 5,119,027 shares of the company’s stock worth $85,744,000 after acquiring an additional 924,027 shares during the last quarter. Janus Henderson Group PLC lifted its holdings in shares of Centessa Pharmaceuticals by 279.2% in the fourth quarter. Janus Henderson Group PLC now owns 4,909,487 shares of the company’s stock worth $82,218,000 after acquiring an additional 3,614,623 shares during the last quarter. Farallon Capital Management LLC boosted its stake in shares of Centessa Pharmaceuticals by 24.3% in the 4th quarter. Farallon Capital Management LLC now owns 3,498,709 shares of the company’s stock valued at $58,603,000 after purchasing an additional 684,391 shares in the last quarter. Finally, Point72 Asset Management L.P. grew its holdings in shares of Centessa Pharmaceuticals by 26.2% during the 4th quarter. Point72 Asset Management L.P. now owns 3,426,599 shares of the company’s stock valued at $57,396,000 after purchasing an additional 710,936 shares during the last quarter. Institutional investors and hedge funds own 82.01% of the company’s stock.

Wall Street Analyst Weigh In

CNTA has been the subject of a number of analyst reports. Guggenheim reiterated a “buy” rating on shares of Centessa Pharmaceuticals in a research report on Monday, February 10th. TD Cowen initiated coverage on Centessa Pharmaceuticals in a report on Tuesday, January 7th. They issued a “buy” rating for the company. Finally, Morgan Stanley reiterated an “overweight” rating and set a $27.00 target price on shares of Centessa Pharmaceuticals in a research report on Friday, March 7th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, Centessa Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $26.00.

Centessa Pharmaceuticals Stock Down 4.0 %

Shares of CNTA opened at $16.51 on Wednesday. The firm has a 50 day simple moving average of $16.45 and a two-hundred day simple moving average of $16.36. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.52 and a quick ratio of 21.52. Centessa Pharmaceuticals has a one year low of $7.75 and a one year high of $19.09. The company has a market cap of $2.18 billion, a P/E ratio of -10.79 and a beta of 1.54.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.